Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00616031
• Other study ID #: TRIC-TRIL-C0702
• Secondary ID: CDR0000584254TRI
• Status: Recruiting
• Phase: Phase 2
• First received: February 14, 2008
• Last updated: August 9, 2013
• Start date: January 2008

Study information

• Verified date: July 2009
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Unspecified
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Nitroglycerin may help carboplatin and paclitaxel work better by making tumor cells more sensitive to the drugs.

PURPOSE: This phase II randomized trial is studying how well giving nitroglycerin together with paclitaxel and carboplatin works and compares it to giving paclitaxel and carboplatin alone in treating patients with previously untreated stage III or stage IV non-small cell lung cancer.

Description:

OBJECTIVES:

• To evaluate tumor response rate and safety of nitroglycerin as a potentiator of anticancer combination therapy comprising paclitaxel and carboplatin in patients with previously untreated stage IIIB or IV non-small cell lung cancer.

OUTLINE: This is a multicenter, randomized, controlled study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive nitroglycerin, paclitaxel, and carboplatin.

• Arm II: Patients receive paclitaxel and carboplatin. In both arms, treatment continues for 6 courses in the absence of disease progression or unacceptable toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed non-small cell lung cancer

• Stage IIIB or IV disease that cannot be treated by radical irradiation

• Tumor lesions must be objectively evaluated according to WHO criteria (maximum diameter is no shorter than twice the slice width and no shorter than 10 mm) by CT scan

• No brain metastasis

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Life expectancy = 3 months

• Neutrophil count > 2,000/µL

• Hemoglobin > 10.0 g/dL

• Platelet count > 100,000/µL

• Serum bilirubin < 2.0 mg/dL

• ALT and AST < 100 IU/L

• Serum creatinine < 2.0 mg/dL

• PaO_2 = 70 mm Hg

• No cardiac problems, including any of the following:

• Poorly controlled hypertension

• Unstable angina

• Congestive heart failure

• Myocardial infarction within the past year

• Ventricular arrhythmia that requires treatment except single, well-controlled isolated ventricular extrasystole

• No chronic active hepatitis or cirrhosis requiring treatment except hepatitis virus carriers who do not need treatment

• No comorbidity of interstitial pneumonia and pulmonary fibrosis requiring treatment

• No other cancer requiring treatment except a malignant tumor curatively resected with no recurrence

• No severe psychiatric disorders including schizophrenia or dementia

• Cardiothoracic ratio < 60% by chest x-ray

• No history of severe drug allergy or allergy to polyoxyethylene castor oil (in some anesthetic drugs or muscle relaxants) or polysorbate 80

• Patients in whom nitroglycerin preparations are contraindicated are not eligible, including any of the following:

• Severe hypotension (e.g., systolic blood pressure = 80 mm Hg)

• Angle-closure glaucoma

• History of hypersensitivity to nitrate/nitrite ester drugs

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy

• Pleurodesis is not considered chemotherapy

• At least 1 week since prior and no other concurrent nitric oxide donors (e.g., nitroglycerin)

• At least 1 week since prior and no concurrent calcium antagonists

• At least 1 week since prior and no concurrent drugs for erectile dysfunction that inhibit phosphodiesterase 5 (e.g., sildenafil citrate or vardenafil hydrochloride hydrate)

• More than 24 hours since prior and no concurrent administration of the following:

• Antifungal azoles, including ketoconazole, miconazole, or itraconazole

• Macrolides, including erythromycin or clarithromycin

• Cyclosporines

• Benzodiazepines, including diazepam, triazolam, or midazolam

• Vitamin A

• Steroid hormones, including ethinylestradiol

• No concurrent participation in another clinical trial

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• carboplatin

• nitroglycerin

• paclitaxel

Locations

Country	Name	City	State
Japan	Kyoto University Hospital	Kyoto

Sponsors (2)

Lead Sponsor	Collaborator
Kyoto University	Translational Research Informatics Center, Kobe, Hyogo, Japan

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor response rate			No
Secondary	Progression-free survival			No
Secondary	Adverse event and its severity			Yes
Secondary	Overall survival			No
Secondary	Change in the plasma concentration of VEGF between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment			No
Secondary	Change in the number of endothelial progenitor cells in blood between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment			No
Secondary	Blood concentration of paclitaxel and carboplatin immediately and two hours after the administration of the anticancer drug (paclitaxel) in the first course of treatment			No